Percheron Therapeutics Limited has released a press release.
Acromegaly Early Access Program Status Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Phase II DMD clinical trial on track for dosing completion
- Phase II clinical trial in DMD Fully Enrolled
- Phase II clinical trial in DMD Update
- Placement to Accelerate Development of ATL1102 in DMD
- Pause in trading
Later from Percheron Therapeutics
- ATL1102 for DMD European regulatory interactions
- Positive preliminary results from ATL1102 DMD Phase II trial
- Response to ASX Price Query
- Appendix 4C - quarterly
- Dosing completed in ATL1102 Phase II DMD trial
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics